A retrospective study sought to confirm real-world outcomes of patients with HER2+ breast cancer treated with trastuzumab deruxtecan.
For local and regional tumors, redlining associations were largest in 1995 to 1999 and attenuated over time. HealthDay News — Associations between historical redlining and breast cancer survival have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results